Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model
Cancer Letters · 2025-02 · 611 · 217444
DOI: 10.1016/j.canlet.2025.217444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-02. Verfasst von Ujjwol Khatri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, Universit…. Hauptthemen laut MEDLINE: Cachexia, Protein Kinase Inhibitors, Pyrazoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Anorexia is a major cause of cancer cachexia and is induced by growth differentiation factor-15 (GDF15), which activates the rearranged during transfection (RET) protein tyrosine kinase in the hindbrain through GDF family receptor α-like (GFRAL), raising the possibility of targeting RET for cancer cachexia treatment. RET-altered cancer patients treated with RET-selective kinase inhibitors gain weight, however, it is unclear whether this results from tumor regression that improves the overall health of patients. Thus, the potential of using a RET inhibitor to address cancer cachexia remains unknown. Using a RET-negative tumor model, we evaluated the activity of the RET-selective inhibitor selpercatinib (LOXO-292) against cancer cachexia. In tumor-bearing animals, selpercatinib significantly increased food consumption, skeletal muscle mass and strength, adipose tissues, and body temperature, as well as reducing body weight loss, without significantly affecting tumor growth. Transcriptomes of skeletal muscle from mock-treated tumor-bearing mice were enriched in starvation and muscle atrophy genes, whereas those from selpercatinib-treated mice were enriched in myoblast proliferation, gluconeogenesis, and insulin receptor signaling genes. In parallel, retrospective analysis of weight gain in selpercatinib-treated patients showed that weight gain was not correlated with tumor response to selpercatinib. Our data demonstrate that selpercatinib could alleviate anorexia and cancer cachexia in an animal model and that weight gain in selpercatinib-treated patients is not dependent on tumor regression. These results identify a RET inhibitor as the first protein tyrosine kinase inhibitor for mitigating cancer cachexia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
- Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA, USA.
- Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Early-Phase Drug Development, Sarah Cannon Research Institute, Nashville, TN, USA. Electronic address:…
- Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electron…
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
Zitieren
APA
Khatri, U., Gouda, M. A., Pandey, S., Chauhan, N. K., Shen, T., Hu, X., Li, M., Huang, S., Subbiah, V., & Wu, J. (2025). Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model. Cancer Letters, 611, 217444. https://doi.org/10.1016/j.canlet.2025.217444
Vancouver
Khatri U, Gouda MA, Pandey S, Chauhan NK, Shen T, Hu X, et al. Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model. Cancer Letters. 2025;611:217444. doi:10.1016/j.canlet.2025.217444
BibTeX
@article{Khatri2025,
author = {Khatri, Ujjwol and Gouda, Mohamed A and Pandey, Shriya and Chauhan, Neeraj K and Shen, Tao and Hu, Xueqing and Li, Min and Huang, Suming and Subbiah, Vivek and Wu, Jie},
title = {Selpercatinib mitigates cancer cachexia independent of anti-tumor activity in the HT1080 tumor model},
journal = {Cancer Letters},
year = {2025},
volume = {611},
pages = {217444},
doi = {10.1016/j.canlet.2025.217444}
}
EUVIMED